Briefly, 4 mm diameter collagen sponges (SpongeCol, Advanced BioMatrix, Carlsbad, CA) were adsorbed with 10 l suspension of either 20 g of rhActivin A (R and D Systems, Minneapolis, MN), 20 g of Activin A

Briefly, 4 mm diameter collagen sponges (SpongeCol, Advanced BioMatrix, Carlsbad, CA) were adsorbed with 10 l suspension of either 20 g of rhActivin A (R and D Systems, Minneapolis, MN), 20 g of Activin A.Nod.FT2L mutant protein, or saline for 30 min at room temperature prior to implantation. Activin A.Nod.F2TL. elife-54582-fig6-data1.xlsx (11K) GUID:?0F4E46BF-6EAE-4733-81BC-BF6B5CD94FC5 Transparent reporting form. elife-54582-transrepform.pdf (303K) GUID:?E6C1529F-5CDE-4B7D-8F16-232BB3889767 Data Availability StatementWe are providing source files for the data shown in the main figures of the manuscript. The following dataset was generated: Aykul S. 2020. Data from: Activin A forms a non-signaling complex with ACVR1 and type II Activin/BMP receptors via its finger 2 tip loop. Dryad Digital Repository. [CrossRef] Abstract Activin A functions in BMP signaling in two ways: it either engages ACVR1B to activate Smad2/3 signaling or binds ACVR1 to form a non-signaling complex (NSC). Even though former house has been analyzed extensively, the roles of the NSC remain unexplored. The genetic disorder fibrodysplasia ossificans progressiva (FOP) provides a unique windows into ACVR1/Activin A signaling because in that disease Activin can either signal through FOP-mutant ACVR1 or form NSCs with wild-type ACVR1. To explore the role of the NSC, we generated agonist-only Activin A muteins that activate ACVR1B but cannot form the NSC with ACVR1. Using one of these muteins, we demonstrate Nrp1 that failure to form the NSC in FOP results in more severe disease pathology. These results provide the first evidence for any biological role for the NSC in vivo and pave the way for further exploration of the NSCs physiological role in corresponding knock-in mice. C has been knocked out (Archambeault and Yao, 2010; Matzuk et al., 1995; Pangas et al., 2007). The results of those experiments have been largely interpreted in Tarloxotinib bromide the context of Activin A acting as an agonist of ACVR1B to induce Smad2/3 or other signaling pathways (Archambeault and Yao, 2010; Makanji et al., 2014; Namwanje and Brown, 2016; Pangas et al., 2007). Interestingly, ACVR1 was originally cloned as the type I receptor for Activin A (Attisano et al., 1993; Tsuchida et al., 1993), but the failure of Activin A to activate ACVR1, Tarloxotinib bromide followed by the discovery that BMP7 activates it, led to a relabeling of ACVR1 as a BMP receptor (Macas-Silva et al., 1998). However, recent studies pinpoint a previously unrecognized house of Activin A: that it can engage the type I receptor ACVR1, to form an ACVR1?Activin A?type II receptor non-signaling complex (NSC) (Hatsell et al., 2015; Olsen et al., 2015). This NSC is unique in that its stoichiometry is usually identical to that of corresponding signaling complexes created between the same receptors and BMPs, but also in that it is converted into a signaling complex in the ACVR1-driven genetic disorder fibrodysplasia ossificans progressiva (FOP). Excluding the special situation of FOP (observe below), the NSC functions to tie down Activin A and render it unavailable for signaling, but also to tie down the type II receptors and ACVR1 and render them unavailable for engagement with BMPs, hence resulting in an apparent inhibition of ACVR1-mediated BMP signaling; in cells where ACVR1 is the main type I receptor, Activin A inhibits BMP6- (Hatsell et al., 2015) and BMP7-induced signaling (this work). The picture is usually more complex in FOP. FOP is usually a rare autosomal-dominant genetic disorder that arises from missense mutations in the sequence encoding the intracellular domain name of ACVR1 (Katagiri et al., 2018). The most clinically important feature of FOP is the episodic, yet progressive and cumulative, formation of heterotopic bone in connective tissue, a process referred to as heterotopic ossification (HO) (Hning and Gillessen-Kaesbach, 2014). FOP-mutant variants of ACVR1 display the neomorphic house of realizing Activin A Tarloxotinib bromide (as well as other Activins) as an agonistic ligand, much Tarloxotinib bromide like a BMP (Hatsell et al., 2015; Hino et al., 2015). In mouse FOP, activation of FOP-mutant ACVR1 by Activin.